ABVD + BACOPP-D-University Hospital Carl Gustav Carus-Hodgkin lymphoma

This refers to a specific therapeutic strategy and clinical trial protocol (Phase 4) developed by the University Hospital Carl Gustav Carus in Dresden for the treatment of Hodgkin lymphoma. The protocol utilizes two distinct multi-drug chemotherapy regimens based on the patient's disease stage: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for limited or intermediate-stage disease, and BACOPP-D (cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin, and vincristine) for advanced-stage disease. BACOPP-D is an etoposide-free modification of the escalated BEACOPP regimen, designed to reduce hematological toxicity and the risk of secondary leukemias. The treatment strategy incorporates 18F-FDG-PET imaging for staging and assessing therapeutic response.

Other names

ABVDBACOPP-DOptimization of Primary Therapy for Hodgkin's Lymphoma protocol